Abstract 2831
Background
The early complete morphological remission (CR) after induction chemotherapy is a major independent prognostic factor for both achievements of CR and long-term outcome in acute myeloid leukemia. we studied the correlation between the serum IL-6 levels and the early morphological CR aiming to use serum level of IL-6 instead of invasive painful BM aspiration as a predictive factor for the early response to induction chemotherapy in AML patients.
Methods
During the study period from February 2015 to May 2016, we investigate 36 patients. Eligibility criteria were the evidence of a diagnosis of AML (not AML-M3), both sexes, age of 18-60 years, Patients with a performance status of 0 to 2, and adequate organs functions. We excluded 6 ineligible patients from the study. All patients received induction chemotherapy of cytarabine and anthracycline in the standard “7 + 3” regimen. We did day 14 BM aspiration to detect the presence of early morphological complete remission (≤ 5% marrow blasts) and blood sampling for measurement of the interleukin-6 at presentation and day 14 of starting of induction chemotherapy.
Results
This study included eligible 30 newly diagnosed AML patients with age ranged from 18-60 years (Mean ± SD, 39.53 ± 13.54). The range of marrow blasts at presentation was 20-93% with the Mean ± SD of 58.10% ± 23.10%. As regards the levels of IL-6 at presentation, the mean ± SD was 42.46 ± 28.10 pg/ml and the range was 21.3 - 140.6. Day 14 BMA revealed 8 out of the 30 enrolled patients achieved complete morphological remission (≤ 5 % marrow blasts). There was a statistically significant decrease in IL-6 serum level in patients achieved morphological CR (mean + SD, 18.26 ± 5.75; range, 10.7 - 28.9 pg/ml) than those did not (mean + SD, 26.07 ± 4.78; range, 21.3 - 32.7 pg/ml) (P = 0.017). At Day 14 of induction chemotherapy, there was a significant positive correlation between IL-6 and marrow blasts (r = 0.745, P = 0.000*).
Conclusions
Interleukin-6 is suggested to be a good predictive marker for early response to induction chemotherapy in patients with acute myeloblastic leukemia and may be used instead of invasive day 14 BM aspiration as a marker of this response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of Medicine, Assiut University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract
5638 - Incidence of Vascular Thromboembolism Events in Cancer Patients Receiving Immunotherapy: A Single Institution Experience.
Presenter: Laura Gutiérrez Sainz
Session: Poster Display session 1
Resources:
Abstract
5182 - High Incidence of Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma.
Presenter: Alaa Abufara
Session: Poster Display session 1
Resources:
Abstract
1504 - Weight Loss over Time in Non-Small Cell Lung Cancer: Results from a Landmark Analysis of 800+ Prospectively-Treated Patients
Presenter: Jennifer Le-rademacher
Session: Poster Display session 1
Resources:
Abstract
3972 - The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC).
Presenter: Salvatore Paiella
Session: Poster Display session 1
Resources:
Abstract
2313 - Impact of Timing and Technique of Gastrostomy Placement on the Outcome of Patients (pts) with Head and Neck Cancer (HNC)
Presenter: M Julia Lostes Bardaji
Session: Poster Display session 1
Resources:
Abstract
5219 - Clinical & nutritional determinants of quality of life in patients with incurable cancer
Presenter: Louise Daly
Session: Poster Display session 1
Resources:
Abstract
4075 - Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer
Presenter: In Gyu Hwang
Session: Poster Display session 1
Resources:
Abstract
4159 - Impact of nutritional derangement on treatment outcome in advanced non-small-cell lung cancer (A-NSCLC) patients (pts).
Presenter: Ilaria Trestini
Session: Poster Display session 1
Resources:
Abstract
1210 - Sarcopenia and pretreatment anemia as prognostic factors for patients with localized muscle invasive bladder cancer treated by neoadjuvant chemotherapy and radical cystectomy
Presenter: Emilien Billon
Session: Poster Display session 1
Resources:
Abstract